Biopure Hemopure New User Fee Likely In November; FDA Requests Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s PDUFA date for Biopure’s hemoglobin-based oxygen carrier Hemopure will likely be in November following the agency’s request for further clarification on the BLA.